References
- Hartwig S, Baldauf JJ, Dominiak-Felden G. Estimation of the epidemiological burden of HPV-related cancers, precancerous lesions, and genital warts in women and men in Europe: potential additional benefit of a nine-valent compared to the quadrivalent HPV vaccine. Papillomavirus Res. 2015;1:90–100.
- Robert Koch Institute. Geman Centre for Registry Cancer Data (Zentrum für Krebsregisterdaten - ZfKD). 2014 [cited 2014 Feb 17]. Available from: http://www.krebsdaten.de/Krebs/DE/Content/ZfKD/zfkd_node.html
- NHS.uk. What is HPV? Berlin: Robert Koch Institute; 2015.
- Introduction of HPV vaccines in European Union countries - an update. European Centre for Disease Prevention and Control [Internet]. London: National Health Services; 2015 [cited 2016 Jul 7]. Available from: http://www.nhs.uk/chq/Pages/2611.aspx.
- Aubin F, Prétet J-L, Jacquard A-C, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a large French National Study (EDiTH IV). Clin Infect Dis. 2008;47(5):610–615.
- Menton JF, Cheng A, Wang M, et al. Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland. Virol J. 2009;6:112.
- Preaud E, Largeron N. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. J Med Econ. 2013;16(6):763–776.
- Kotsopoulos N, Connolly MP, Remy V. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Econ Rev. 2015;5(1):54.
- Horn J, Damm O, Kretzschmar MEE, et al. Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013;31(19):2372–2380.
- Seidel D, Becker N, Rohrmann S, et al. Socio-demographic characteristics of participation in the opportunistic German cervical cancer screening programme: results from the EPIC-Heidelberg cohort. J Cancer Res Clin Oncol. 2009;135(4):533–541.
- Hillemanns P, Mallmann P, Beckmann MW. New screening proposals: the federal joint commission defines the parameters for cervical cancer screening from 2018: statement of the gynecology oncology working group (AGO). Geburtshilfe Frauenheilkd. 2016;76(2):145–146.
- European Medicine Agency - Committee for Medicinal Products for Human Use. Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - Summary of opinion. European Medicine Agency, Committee for Medicinal Products for Human Use. London: European Medicine Agency.
- European Medicines Agency. Gardasil, Summary of Product Characteristics [Internet]. 2015 [cited 2016 Jul 7]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp
- European Medicines Agency. Cervarix, summary of product characteristics. 2015 [cited 2016 Jul 7]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124
- Rieck T, Feig M, Deleré Y, et al. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine. 2014;32(43):5564–5569.
- Hense S, Hillebrand K, Horn J, et al. HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729–1733.
- Delere Y, Böhmer MM, Walter D, et al. HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccin Immunother. 2013;9(8):1706–1711.
- Robert Koch Institute. Recommendations of the standing committee on vaccination (STIKO) at the Robert Koch Institute /effective: August 2014. Berlin: Robert Koch Institute; 2015.
- Poethko-Muller C, Buttmann-Schweiger N, Ki GGSSG. [HPV vaccination coverage in German girls: results of the KiGGS study: first follow-up (KiGGS Wave 1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(7):869–877.
- Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–935.
- Merck. Merck’s investigational 9-valent HPV vaccine, V503, prevented 97 percent of cervical, vaginal and vulvar pre-cancers caused by five additional HPV types, in phase III study. 2015 [cited 2014 Dec 1]; Available from: http://www.mercknewsroom.com/news-release/research-and-development-news/mercks-investigational-9-valent-hpv-vaccine-v503-prevente
- Summary of opinion Gardasil 9 human papillomavirus 9-valent vaccine (recombinant, adsorbed). 2015, European Medicine Agency, Committee for Medicinal Products for Human Use.
- Jit M. Cost effectiveness of elimination of HPV-related cancers, in 5th Helsinki HPV workshop on vaccination women and men against premature death. Helsinki: Helsinki HPV Seminar; 2016.
- Brisson M. Incremental cost-effectiveness of the 9-valent vs. the 4-valent HPV vaccine in the U.S., in Advisory Committee on Immunization Practices (ACIP) meeting. Atlanta: ACIP; 2014.
- Weiss TP, Dasbach M, Potential health and economic impact of the investigational 9-valent HPV vaccine in the United States, In International Papillomavirus Conference. 2014: Seattle.
- Chesson H. Overview of cost-effectiveness of 9-valent HPV vaccination, in Advisory Committee on Immunization Practices. Atlanta; 2015.
- Drolet M, Laprise J-F, Boily M-C, et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264–2268.
- Boiron L, Joura E, Largeron N, et al. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent Hpv vaccine in Austria. Value in Health. 2015;18(7):A585.
- Hillemanns P, Petry KU, Largeron N, et al. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health. 2009;17:77–86.
- Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2(1):19. .
- Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28–41. .
- Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–6867. .
- Elbasha EH, Dasbach EJ. An integrated economic evaluation and HPV disease transmission models - technical report accompanying the manuscript impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–6867.
- German Federal Statistics Office. Facts & figures -> society & state ->population ->deaths, life expectancy. https://www.destatis.de/EN/FactsFigures/SocietyState/Population/Deaths/Deaths.html;jsessionid=4F274DF95FF7F226BB3576989FBA7AE7.cae2 [Internet]. 2015 [cited 2016 Jul 7]. Available from: https://www.destatis.de/EN/FactsFigures/SocietyState/Population/Deaths/Deaths.html
- National Survey of Sexual Attitudes and Life Styles III. N.S.f.S. Research, Editor. London: NATSAL.
- Federal Statistics Office (Statistisches Bundesamt), Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik) Diagnosen, Prozeduren, Fallpauschalen und Case Mix der vollstationären Patientinnen und Patienten in Krankenhäusern [Internet]. 2014 [cited 2016 Jul 7]. Avaliable from: https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/OperationenProzeduren5231401137014.pdf?__blob=publicationFile
- Sroczynski G, Schnell-Inderst P, Mühlberger N, et al. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess. 2010;6:Doc05.
- Rϋckinger S, Tauscher M, Redel R, et al. Participation in cervical cancer screening by age and region–a cohort study with a 3 1/2 year follow-up on 2,223,135 women in Bavaria. Gesundheitswesen. 2008;70(6):e17–e21.
- Kerek-Bodden HA, Brenner GL, Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten [Internet]. 2008 [cited 2016 Jul 7]. http://www.ag-cpc.de/media/ZI-Abschlussbericht-080602.pdf
- McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ). 1999;5:1–6.
- Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810–819.
- Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;91(4):626–631.
- Insinga RP, Dasbach EJ, Elbasha EH, et al. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer. 2007;2:15.
- Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):1158–1171.
- Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9(1):37–48.
- Ho GY, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev. 2004;13(1):110–116.
- Onda T, Carter JJ, Koutsky LA, et al. Characterization of IgA response among women with incident HPV 16 infection. Virology. 2003;312(1):213–221.
- Federal Statistics Office (Statistisches Bundesamt). Mortality Table Germany 2010-12 [Internet]. 2015 [cited 2016 Jul 7]. Available from: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/SterbetafelDeutschland.xlsx?__blob=publicationFile
- German Federal Statiscs Office. Facts & figures -> society & state ->population ->current population. 2015 [cited 2015; Available from: https://www.destatis.de/EN/FactsFigures/SocietyState/Population/CurrentPopulation/CurrentPopulation.html
- Zechmeister I, Blasio BF, Garnett G, et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27(37):5133–5141.
- Schmitt DP. Sociosexuality from Argentina to Zimbabwe: a 48-nation study of sex, culture, and strategies of human mating. Behav Brain Sci. 2005;28(2):247–275.
- Petry KU, Page K, Stein ES, et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis. 2012;12:367.
- Petry KU, Luyten A, Justus A, et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84–results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis. 2013;13:135.
- Luyten A, Buttmann-Schweiger N, Luyten K, et al. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer. 2014;135(6):1408–1416.
- Cancer Research UK. Cervical cancer survival statistics. [cited 2014 Nov 27. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/cervix/survival/2014
- Istituto Nazionale Tumori and Istituto Superiore di Sanità, Eurocare Survival of cancer patient in Europe [Internet]. 2015 [cited 2016 Jul 7]. Available from: http://www.eurocare.it/.
- Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
- Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–1868.
- Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943.
- Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–411.
- Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–1702.
- Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–1585.
- Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927.
- Federal Statiscs Office (Statistisches Bundesamt). German consumer price index (CPI). 2015 [cited 2015 Aug 12]; Available from: https://www.destatis.de/EN/FactsFigures/NationalEconomyEnvironment/Prices/ConsumerPriceIndices/Tables_/ConsumerPricesCategories.html?cms_gtp=151232_list%253D3%2526151226_slot%253D2&https=1
- Petry KU, Breugelmans JG, Bénard S, et al. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. 2008;29(4):345–349.
- Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804.
- Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):500–507.
- Siebert U, Muth C, Sroczynski G, et al. Liquid-based preparation and computer-assisted examination of cervical smears. Clinical effectiveness, economic evaluation and systematic decision analysis. Health Technol Assess. 2004;1–444. https://www.mig.tu-berlin.de/fileadmin/a38331600/2004.publications/2004.siebert_hta.35.pdf in Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security
- Hampl M, Hahn JA, Delwart E, et al. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre. BMC Infect Dis. 2011;11:73.
- Brisson M, Laprise J-F, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine. 2013;31(37):3863–3871.
- Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76.
- Rote Liste Service GmbH. Gardasil Price. 2016 [cited 2016 Feb 08]; Available from: http://online.rote-liste.de/suche/praep/20976
- Lauer Fischer. Gardasil 9 Price. 2016. [cited 2016 March 15]. Available from: http://www2.lauer- fischer.de/produkte/lauer-taxe/lauer-taxe/
- Hinz A, Klaiberg A, Brähler E, et al. The Quality of Life Questionnaire EQ-5D: modelling and norm values for the general population. Psychother Psychosom Med Psychol. 2006;56(2):42–48.
- Klussmann JP, Schädlich PK, Chen X, et al. Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. Clinicoecon Outcomes Res. 2013;5:203–213.
- Kraut AA, Schink T, Schulze-Rath R, et al. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis. 2010;10:360.
- Hartwig S, Syrjänen S, Dominiak-Felden G, et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer. 2012;12:30.
- Health & Social Care Information Centre, Cervical Screening Programme, England 2013-14. 2015.
- Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2013. 2014 [cited 2014 Jan 19]. Available from: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-322718
- Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489–498.
- Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG. 2011;118(9):1031–1041.
- Soergel P, Makowski L, Schippert C, et al. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccin Immunother. 2012;8(2):243–251.
- Lerner D, Parsons SK, Justicia-Linde F, et al. The impact of precancerous cervical lesions on functioning at work and work productivity. J Occup Environ Med. 2010;52(9):926–933.